




143885

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 237/20, 237/34, A61K 31/50	A1	(11) International Publication Number: WO 98/46574 (43) International Publication Date: 22 October 1998 (22.10.98)
(21) International Application Number: PCT/EP98/02172 (22) International Filing Date: 14 April 1998 (14.04.98) (30) Priority Data: 9707693.9 16 April 1997 (16.04.97) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): HARLING, John, David [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). HERDON, Hugh, Jonathan [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). ORLEK, Barry, Sidney [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). THOMPSON, Mervyn [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).		(74) Agent: WEST, Vivien; SmithKline Beecham, Corporate Intellectual Property, New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: PYRIDAZINE AND PHTHALAZINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS ANTICONVULSANTS



(57) Abstract

A method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntington's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia and narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysesthesias in diseases such as diabetes, MS and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS) comprises administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof in which the ring system Q is pyridazinyl or phthalazinyl; the ring system P is phenyl or pyridyl; R¹ is hydrogen, C₁₋₆ alkyl, phenyl or C₁₋₆ alkylphenyl; R² is hydrogen or C₁₋₆ alkyl; R³ is hydrogen or up to three substituents selected from halogen, CN, trifluoromethyl, trifluoromethoxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxy carbonyl, phenyl, phenoxy, phenylC₁₋₆ alkyl, benzyloxy, or benzoyl.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PYRIDAZINE AND PHTHALAZINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS ANTICONVULSANTS

This invention relates to a novel method of treatment and to novel compounds for use in that method.

5

GB-A-2063249 (Mitsubishi Yuca) discloses a group of 4-phenylphthalazine derivatives having inhibitory activity against platelet aggregation and so useful for treatment of cerebral thrombosis, cerebral infarction, myocardial infarction and arteriosclerotic diseases.


- 10 DE-A-3517617 (Lentia) discloses pyridazinamine compounds which are used as pyridazinammonium compounds coupled with a halogen ion as algicides, bactericides and fungicides.

15 Leick, Chem. Ber., 1905, 38, 3923 describes the preparation of the compound phenyl-(4-phenyl-phthalazin-1-yl)-amine.

It has now been surprisingly found that compounds of formula (I) below possess anti-convulsant activity and are therefore believed to be useful in the treatment and/or prevention of anxiety, mania, depression, panic disorders and/or aggresssion, disorders associated with
20 a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia,
25 obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, MS and motor neurone disease,
30 ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS).

Accordingly the present invention provides a method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggresssion, disorders associated with a
35 subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's

disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesis in diseases such as diabetes, MS and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS) comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof:



(I)

- 15 in which the ring system Q is pyridazinyl or phthalazinyl
 the ring system P is phenyl or pyridyl
 R¹ is hydrogen, C₁₋₆ alkyl, phenyl or C₁₋₆ alkylphenyl.
 R² is hydrogen or C₁₋₆ alkyl
 R³ is hydrogen or up to three substituents selected from halogen, CN,
 20 trifluoromethyl, trifluoromethoxy, C₁₋₆ alkyl, C₁₋₆ alkoxy,
 C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxycarbonyl, phenyl, phenoxy,
 phenylC₁₋₄alkyl, benzyloxy, or benzoyl.

The compounds of use in this invention are typically optionally substituted phenyl-
 25 (pyridazinyl)-amines, especially (6-phenyl-pyridazin-3-yl)-amines, or optionally substituted
 phenyl-(phthalazinyl)-amines, especially (4-phenyl-phthalazin-1-yl)-amines. The phenyl or
 pyridyl group P is typically mono or di-substituted by substituent R³ when R³ is other than
 hydrogen.

- 30 In formula (I), alkyl groups, including alkyl groups that are part of another moiety, may be
 straight chain or branched. Aromatic rings that are unsubstituted, including rings that are
 part of another moiety, may optionally be substituted with one or more substituents
 independently selected from halogen or C₁₋₆ alkyl, C₁₋₆ alkoxy or C₁₋₆ alkylcarbonyl.

Suitable halo substituents include fluoro, chloro, iodo and bromo.

A suitable group of compounds of formula (I) have

- 5 R^1 as hydrogen, phenyl or methylphenyl
 R^2 as hydrogen or methyl
 R^3 as hydrogen, methyl, ethyl, *t*-butyl, methoxy, trifluoromethyl,
 trifluoromethoxy, benzoyl, ethoxycarbonyl, chloro, fluoro or cyano.

When P is phenyl, preferably R^3 represents a 3-substituent or a 3,5-disubstitution.

10

Examples of compounds of formula (I) are:

- 3-chlorophenyl-(6-phenylpyridazin-3-yl)-amine
3-benzoylphenyl-(6-phenylpyridazin-3-yl)-amine
2-methoxyphenyl-(6-phenylpyridazin-3-yl)-amine
15 3-chlorophenyl-(4-methyl-6-phenylpyridazin-3-yl)-amine
phenyl-(4-phenyl-phthalazin-1-yl)-amine
3-chlorophenyl-(phthalazin-1-yl)-amine
4-chlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
3,5-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
20 4-fluorophenyl-(4-phenyl-phthalazin-1-yl)-amine
4-*t*-butylphenyl-(4-phenyl-phthalazin-1-yl)-amine
3-fluorophenyl-(4-phenyl-phthalazin-1-yl)-amine
2-chlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
3,4-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
25 2,6-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
2,3-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
3-ethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
3,4-dimethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
2-ethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
30 2,3-dimethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
2-*t*-butylphenyl-(4-phenyl-phthalazin-1-yl)-amine
3-trifluoromethoxyphenyl-(4-phenyl-phthalazin-1-yl)-amine
2-trifluoromethoxyphenyl-(4-phenyl-phthalazin-1-yl)-amine
3-benzoylphenyl-(4-phenyl-phthalazin-1-yl)-amine
35 3-cyanophenyl-(4-phenyl-phthalazin-1-yl)-amine
3-ethoxycarbonylphenyl-(4-phenyl-phthalazin-1-yl)-amine
3-trifluoromethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
3-pyridyl-(4-phenyl-phthalazin-1-yl)-amine

3-chlorophenyl-(4-phenyl-phthalazin-1-yl)-amine

When synthesised, these compounds may be in salt form, and such salts also form part of this invention. Such salts may be used in preparing pharmaceutically acceptable salts. The
5 compounds and their salts may be obtained as solvates, such as hydrates, and these also form part of this invention.

The use of above-listed compounds and pharmaceutically acceptable salts thereof, especially the hydrochloride, and pharmaceutically acceptable solvates, especially hydrates, forms a
10 preferred aspect of the present invention.

The administration of such compounds to a mammal may be by way of oral, parenteral, sub-lingual, nasal, rectal, topical or transdermal administration.

- 15 An amount effective to treat the disorders hereinbefore described depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50, 100, 200, 300 and 400 mg of the active compound. Unit doses will normally be
20 administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 1 to 500 mg, that is in the range of approximately 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg/day, for example 1 to 6 mg/kg/day.
- 25 It is greatly preferred that the compound of formula (I) is administered in the form of a unit-dose composition, such as a unit dose oral, including sub-lingual, nasal, rectal, topical or parenteral (especially intravenous) composition.

Such compositions are prepared by admixture and are suitably adapted for oral or parenteral
30 administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.

35 Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

5

These solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

10

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl *p*-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

20

Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.

25

For parenteral administration, fluid unit dose forms are prepared containing the compound and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

30

Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.

35

As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

Accordingly, in a further aspect, the present invention provides a pharmaceutical

- 5 composition for use in the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggresssion, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's
- 10 disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain,
- 15 dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, MS and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS) which comprises a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

20


- In a further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggresssion, disorders associated with a subarachnoid haemorrhage or neural shock, the
- 25 effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological
- 30 deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, MS and motor neurone disease, ataxias, muscular rigidity (spasticity),
- 35 temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS).

Among the compounds proposed for use in the method of treatment of this invention, the following are believed to be novel compounds:

- (a) compounds of formula (I) in which R^1 is hydrogen
- (b) compounds of formula (I) in which P is pyridyl and R^3 is as defined;
- (c) compounds of formula (I) in which Q is pyridazinyl, R^1 is other than hydrogen and R^3 is a substituent other than halogen
- 5 (d) compounds of formula (I) in which Q is phthalazinyl, R^1 is other than hydrogen and R^3 is phenyl, phenoxy, phenylC₁₋₄alkyl, benzyloxy, or benzoyl
- (e) the compounds
 - 3-benzoylphenyl-(6-phenylpyridazin-3-yl)-amine
 - 2-methoxyphenyl-(6-phenylpyridazin-3-yl)-amine
 - 10 3-chlorophenyl-(4-methyl-6-phenylpyridazin-3-yl)-amine
 - 3-chlorophenyl-(phthalazin-1-yl)-amine
 - 3,5-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
 - 2,6-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
 - 2,3-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
 - 15 3-ethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
 - 2-*t*-butylphenyl-(4-phenyl-phthalazin-1-yl)-amine
 - 3-trifluoromethoxyphenyl-(4-phenyl-phthalazin-1-yl)-amine
 - 2-trifluoromethoxyphenyl-(4-phenyl-phthalazin-1-yl)-amine
 - 3-benzoylphenyl-(4-phenyl-phthalazin-1-yl)-amine
 - 20 3-cyanophenyl-(4-phenyl-phthalazin-1-yl)-amine
 - 3-ethoxycarbonylphenyl-(4-phenyl-phthalazin-1-yl)-amine
 - 3-pyridyl-(4-phenyl-phthalazin-1-yl)-amine

In a further aspect the invention provides the use of a novel compound of this invention, or
 25 a pharmaceutically acceptable salt or solvate, thereof as a therapeutic agent, in particular for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggresssion, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive
 30 agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury,
 35 tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, MS and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS).


Compounds of formula (I) used in this invention may be prepared by reacting an amino compound of formula (II)



(II)

where $\text{R}^{3\text{A}}$ is R^3 as defined for formula (I) or a group convertible to R^3 and P is defined for formula (I).

with a compound of formula (III)



(III)

where Y is a group displaceable with an amine of formula (II) and $\text{R}^{1\text{A}}$ and $\text{R}^{2\text{A}}$ are R^1 and R^2 as defined for formula (I) or groups convertible to R^1 and R^2 , and Q is as defined for formula (I),

and where required converting a $\text{R}^{1\text{A}}$, $\text{R}^{2\text{A}}$ or $\text{R}^{3\text{A}}$ group to a R^1 , R^2 or R^3 group, converting one R^1 , R^2 or R^3 group to another R^1 , R^2 or R^3 group,

converting a salt product to the free base or another pharmaceutically acceptable salt, or converting a free base product to a pharmaceutically acceptable salt.

Typically Y is a halogen, especially chloro, and the reaction is carried out by heating the reactants (II) and (III) at around 100 °C. Further details of procedures for the preparation of compounds for use in this invention can be found in the references cited above and by study of the Examples below.

Conversions of an $\text{R}^{1\text{A}}$, $\text{R}^{2\text{A}}$ or $\text{R}^{3\text{A}}$ group to a R^1 , R^2 or R^3 group typically arise when a protecting group is needed during the above coupling reaction or during the preparation of the reactants by the procedures described below. Interconversion of one R^1 , R^2 or R^3 group

to another typically arises when one compound of formula (I) is used as the immediate precursor of another compound of formula (I), or when it is easier to introduce a more complex or reactive substituent at the end of a synthetic sequence.

- 5 Compounds of formula (II) are commercially available or can be prepared by conventional substitution of commercially available aniline derivatives.

Compounds of formula (III) can be prepared by further substitution of commercially available compounds using conventional procedures and by analogy with the procedures set
10 out in the references cited above and in the Descriptions below.

The preparation of compounds used in this invention is further illustrated by the following Descriptions and Examples. The utility of the compounds in the method of treatment of this invention is shown by the Pharmacological Data that follow the Examples.

15

Example 1

3-Chlorophenyl-(6-phenylpyridazine-3-yl)-amine

A stirred mixture of 3-chloro-6-phenylpyridazine (1.5g, 7.87mmol) and 3-chloroaniline
20 (6.05ml, 39.3mmol) was heated to 100°C for 1 h. On cooling, chloroform was added and the mixture washed with a large excess of sodium hydroxide solution (5%) and water. The organic layer was dried (NaSO₄) and concentrated *in vacuo* to afford a brown oil which solidified on standing. Recrystallisation from ethanol gave the title compound as a beige solid. (0.2g). m.p. 199°C

25

¹H NMR (DMSO-d₆) δ: 7.04 (1H, d, J=6Hz) 7.25 (1H, d, J=6Hz) 7.35 (1H, t, J=6Hz) 7.53 (4H, m) 8.04 (3H, d, J=6Hz) 8.20 (1H s) 9.65 (1H s); m/z (API⁺): 282 (M+H⁺)

The compounds of Examples 2 to 4 were made using a procedure similar to that used in
30 Example 1.

Example 2

3-Benzoylphenyl-(6-phenylpyridazin-3-yl)-amine

35 ¹H NMR (DMSO-d₆) δ: 7.10 - 7.75 (9H, m), 7.80 (2H, d, J = 8Hz), 8.05 (3H, m), 8.20 (2H, m), 9.65 (1H, s); m/z (CI): 352 (M+H)⁺

Example 3**2-Methoxyphenyl-(6-phenylpyridazin-3-yl)-amine**

m.p. 102-4°C

5

Example 4**3-Chlorophenyl-(4-methyl-6-phenylpyridazin-3-yl)-amine**

m.p. 155-6°C

10

Description 1**1-Chloro-4-phenyl-phthalazine**

A solution of 4-phenyl-1-phthalazinone (10g, 45mmol) in POCl₃ was stirred whilst N,N-dimethylaniline was added dropwise over 0.5 h. The resultant mixture was heated under reflux for 1.5 h. then allowed to cool and added very slowly to stirred ice. The resultant suspension was filtered and washed with water to afford a pink solid.(6.5g)

15

20

¹NMR (DMSO-d₆) δ: 7.70 (5H, m) 7.05 (1H, d, J=6Hz) 8.20 (2H, m) 8.45 (1H, d, J=6Hz);
m/z (API⁺): 241 (M+H)⁺

Example 5**Phenyl-(4-phenyl-phthalazin-1-yl)-amine**

A stirred mixture of 1-chloro-4-phenylphthalazine D1 (1.5g, 6.2mmol) and aniline (2.89g 31mmol) was heated to 100°C for 1 h. The mixture was cooled, chloroform added and the whole washed with 5% sodium hydroxide, water and dried (NaSO₄) Evaporation *in vacuo* afforded a residue which on recrystallisation from ethanol gave the title compound as a pale yellow solid (0.52g). m.p. 230°C.

30

¹NMR (DMSO-d₆)δ: 7.05 (1H, t, J=6Hz) 7.45(2H, t, J=6Hz) 7.61 (5H, m) 7.97 (5H, m) 8.68 (1H, d, J=6Hz) 9.29 (1H, s); m/z (API⁺): 298 (M+H)⁺

The compounds of Examples 6 to 28 were prepared in a similar way to the method of Example 5.

35

Example 6**3-Chlorophenyl-(phthalazin-1-yl)-amine**

- 5 ^1H NMR (DMSO- d_6) δ : 7.08 (1H, dd), 7.39 (1H, t, $J = 6$ Hz), 7.86 (1H, dd), 8.04 (2H, m), 8.25 (1H, d, $J = 2$ Hz), 8.60 (1H, d, $J = 6$ Hz), 9.20 (1H, s), 9.35 (1H, s);
 m/z (API): 256 ($M+H^+$, 100%)

Example 7

10

4-Chlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
m.p. 199°C**Example 8**

15

3,5-Dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
m.p. 256-8°C**Example 9**

20

4-Fluorophenyl-(4-phenyl-phthalazin-1-yl)-amine
m.p. 228-9°C**Example 10**

25

4-*t*-Butylphenyl-(4-phenyl-phthalazin-1-yl)-amine
m.p. 282-3°C**Example 11**

30

3-Fluorophenyl-(4-phenyl-phthalazin-1-yl)-amine
m.p. 235-7°C.**Example 12**

35

2-Chlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
m.p. 167-8°C

Example 13

3,4-Dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
m.p. 212-3°C

5

Example 14

2,6-Dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine

10 m/z (API⁺): 366 (M+H⁺, 100%)

Example 15

15 **2,3-Dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine**
m.p. 165-7°C

Example 16

20 **3-Ethylphenyl-(4-phenyl-phthalazin-1-yl)-amine**
m.p. 195-6°C

Example 17

25 **3,4-Dimethylphenyl-(4-phenyl-phthalazin-1-yl)-amine**
m.p. 204-6°C

Example 18

30 **2-Ethylphenyl-(4-phenyl-phthalazin-1-yl)-amine**
m.p. 173-4°C

Example 19

35 **2,3-Dimethylphenyl-(4-phenyl-phthalazin-1-yl)-amine**
m.p. 243-4°C

Example 20**2-*t*-Butylphenyl-(4-phenyl-phthalazin-1-yl)-amine**5 m/z (AP⁺): 354 (M+H⁺, 100%)**Example 21****3-Trifluoromethoxyphenyl-(4-phenyl-phthalazin-1-yl)-amine**

10 m.p. 184-5°C

Example 22**2-Trifluoromethoxyphenyl-(4-phenyl-phthalazin-1-yl)-amine**

15 m.p. 246°C

Example 23**3-Benzoylphenyl-(4-phenyl-phthalazin-1-yl)-amine**

20 m.p. 208-9°C

Example 24**3-Cyanophenyl-(4-phenyl-phthalazin-1-yl)-amine**

25 m.p. 250-1°C

Example 25**3-Ethoxycarbonylphenyl-(4-phenyl-phthalazin-1-yl)-amine**

30 m.p. 194-5°C

Example 26**3-Trifluoromethylphenyl-(4-phenyl-phthalazin-1-yl)-amine**

35 m.p. 176-7°C

Example 27**3-Pyridyl-(4-phenyl-phthalazin-1-yl)-amine**

¹H NMR (DMSO-d⁶) δ: 7.55 (1H, m), 7.65 - 7.80 (5H, m), 7.95 - 8.20 (5H, m), 8.35 (1H, m), 8.50 (1H, br m), 8.75 (1H, d, J = 9Hz), 9.18 (1H, s), 9.55 (1H, br s);
m/z (API⁺): 299 (M+H⁺).

Example 28**10 3-Chlorophenyl-(4-phenyl-phthalazin-1-yl)-amine**

m.p. 194°C

m/z (API⁺): 333, 331 (M+H⁺).**PHARMACOLOGICAL DATA**

15

1. Binding Assay Method

WO 92/22293 (SmithKline Beecham) discloses compounds having anti-convulsant activity, including *inter alia* the compound *trans*-(+)-6-acetyl-4S-(4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol (hereinafter referred to as Compound A). It has been found that the compounds of WO 92/22293 bind to a novel receptor obtainable from rat forebrain tissue, as described in WO 96/18650 (SmithKline Beecham). The affinity of test compounds to the novel receptor site is assessed as follows.

25 Method

Whole forebrain tissue is obtained from rats. The tissue is first homogenised in buffer (usually 50mM Tris/HCl, pH 7.4). The homogenised tissue is washed by centrifugation and resuspension in the same buffer, then stored at -70°C until used.

30

To carry out the radioligand binding assay, aliquots of tissue prepared as above (usually at a concentration of 1-2mg protein/ml) are mixed with aliquots of [3H]-Compound A dissolved in buffer. The final concentration of [3H]-Compound A in the mixture is usually 20nM. The mixture is incubated at room temperature for 1 hour. [3H]-Compound A bound to the tissue is then separated from unbound [3H]-Compound A by filtration through Whatman GF/B glass fibre filters. The filters are then washed rapidly with ice-cold buffer. The amount of radioactivity bound to the tissue trapped on the filters is measured by addition of liquid scintillation cocktail to the filters followed by counting in a liquid scintillation counter.

35

In order to determine the amount of "specific" binding of [3H]-Compound A, parallel assays are carried out as above in which [3H]-Compound A and tissue are incubated together in the presence of unlabelled Compound A (usually 3 μ M). The amount of binding of [3H]-Compound A remaining in the presence of this unlabelled compound is defined as "non-specific" binding. This amount is subtracted from the total amount of [3H]-Compound A binding (i.e. that present in the absence of unlabelled compound) to obtain the amount of "specific" binding of [3H]-Compound A to the novel site.

The affinity of the binding of test compounds to the novel site can be estimated by incubating together [3H]-Compound A and tissue in the presence of a range of concentrations of the compound to be tested. The decrease in the level of specific [3H]-Compound A binding as a result of competition by increasing concentrations of the compound under test is plotted graphically, and non-linear regression analysis of the resultant curve is used to provide an estimate of compound affinity in terms of pKi value.

Results

Compounds of Formula (I) were active in this test. For example, compounds of Examples 1, 4, 5, 8, 13, 24, 26 and 28 gave pKi values greater than 6.5.

2. MEST Test

The maximal electroshock seizure (MEST) threshold test in rodents is particularly sensitive for detecting potential anticonvulsant properties¹. In this model, anticonvulsant agents elevate the threshold to electrically-induced seizures whilst proconvulsants lower the seizure threshold.

Method

Mice (naive male, Charles River, U.K. CD-1 strain, 25 - 30g) are randomly assigned to groups of 10 - 20 and dosed orally or intraperitoneally at a dose volume of 10 ml/kg with various doses of compound (0.3 - 300 mg/kg) or vehicle. Mice are then subjected at 30 or 60 min post dose to a single electroshock (0.1 sec, 50Hz, sine wave form) administered via corneal electrodes. The mean current and standard error required to induce a tonic seizure in 50% (CC₅₀) of the mice in a particular treatment group is determined by the 'up and down' method of Dixon and Mood (1948)². Statistical comparisons between vehicle- and drug-treated groups are made using the method of Litchfield and Wilcoxon (1949)³.

In control animals the CC₅₀ is usually 14 - 18 mA. Hence the first animal in the control group is subjected to a current of 16 mA. If a tonic seizure does not ensue, the current is increased for a subsequent mouse. If a tonic convulsion does occur, then the current is decreased, and so on until all the animals in the group have been tested.

5

The percentage increase or decrease in CC₅₀ for each group compared to the control is calculated.

10

Studies are carried out using a Hugo Sachs Elektronik Constant Current Shock Generator with totally variable control of shock level from 0 to 300 mA and steps of 2 mA are usually used.

Drugs are suspended in 1% methyl cellulose.

15 References

1. Loscher, W. and Schmidt, D. (1988). *Epilepsy Res.*, **2**, 145-181
2. Dixon, W.J. and Mood, A.M. (1948). *J. Amer. Stat. Assn.*, **43**, 109-126
3. Litchfield, J.T. and Wilcoxon, F.(1949). *J. Pharmacol. exp. Ther.*, **96**, 99-113

20


Results

25

Compounds of formula (I) dosed by the oral route as a suspension in methyl cellulose and tested one hour post dosing showed an increase in seizure threshold. For example, the compound of Example 28 showed a 17% increase at 10 mg/kg and a 67% increase when dosed in saline at 5 mg/kg i.v.

Claims

1. A method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggresssion, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, MS and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS) comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof:



(I)

in which the ring system Q is pyridazinyl or phthalazinyl

the ring system P is phenyl or pyridyl

R¹ is hydrogen, C₁₋₆ alkyl, phenyl or C₁₋₆ alkylphenyl.

R² is hydrogen or C₁₋₆ alkyl

R³ is hydrogen or up to three substituents selected from halogen, CN, trifluoromethyl, trifluoromethoxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆alkylcarbonyl, C₁₋₆alkoxycarbonyl, phenyl, phenoxy, phenylC₁₋₄alkyl, benzyloxy, or benzoyl.

2. A pharmaceutical composition for use in the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggresssion, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from

substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia,

- 5 obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, MS and motor neurone disease,
- 10 ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS) which comprises a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

3. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of
- 15 anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's
- 20 disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal
- 25 neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, MS and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS).

- 30 4. A method according to claim 1, pharmaceutical composition according to claim 2, or use according to claim 3, wherein the compound of formula (I) is selected from the group consisting of:

3-chlorophenyl-(6-phenylpyridazin-3-yl)-amine

3-benzoylphenyl-(6-phenylpyridazin-3-yl)-amine

- 35 2-methoxyphenyl-(6-phenylpyridazin-3-yl)-amine

3-chlorophenyl-(4-methyl-6-phenylpyridazin-3-yl)-amine

phenyl-(4-phenyl-phthalazin-1-yl)-amine

3-chlorophenyl-(phthalazin-1-yl)-amine

- 4-chlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
3,5-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
4-fluorophenyl-(4-phenyl-phthalazin-1-yl)-amine
4-*t*-butylphenyl-(4-phenyl-phthalazin-1-yl)-amine
5 3-fluorophenyl-(4-phenyl-phthalazin-1-yl)-amine
2-chlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
3,4-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
2,6-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
2,3-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
10 3-ethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
3,4-dimethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
2-ethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
2,3-dimethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
2-*t*-butylphenyl-(4-phenyl-phthalazin-1-yl)-amine
15 3-trifluoromethoxyphenyl-(4-phenyl-phthalazin-1-yl)-amine
2-trifluoromethoxyphenyl-(4-phenyl-phthalazin-1-yl)-amine
3-benzoylphenyl-(4-phenyl-phthalazin-1-yl)-amine
3-cyanophenyl-(4-phenyl-phthalazin-1-yl)-amine
3-ethoxycarbonylphenyl-(4-phenyl-phthalazin-1-yl)-amine
20 3-trifluoromethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
3-pyridyl-(4-phenyl-phthalazin-1-yl)-amine
3-chlorophenyl-(4-phenyl-phthalazin-1-yl)-amine.

5. A compound of formula (I) as defined in claim 1, wherein: R^1 is hydrogen; and/or
25 P is pyridyl and R^3 is as defined; and/or Q is pyridazinyl, R^1 is other than hydrogen and R^3
is a substituent other than halogen; and/or Q is phthalazinyl, R^1 is other than hydrogen and
 R^3 is phenyl, phenoxy, phenylC₁₋₄alkyl, benzyloxy, or benzoyl.

6. A compound selected from the group consisting of:
30 3-benzoylphenyl-(6-phenylpyridazin-3-yl)-amine
2-methoxyphenyl-(6-phenylpyridazin-3-yl)-amine
3-chlorophenyl-(4-methyl-6-phenylpyridazin-3-yl)-amine
3-chlorophenyl-(phthalazin-1-yl)-amine
3,5-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
35 2,6-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
2,3-dichlorophenyl-(4-phenyl-phthalazin-1-yl)-amine
3-ethylphenyl-(4-phenyl-phthalazin-1-yl)-amine
2-*t*-butylphenyl-(4-phenyl-phthalazin-1-yl)-amine


- 3-trifluoromethoxyphenyl-(4-phenyl-phthalazin-1-yl)-amine
 2-trifluoromethoxyphenyl-(4-phenyl-phthalazin-1-yl)-amine
 3-benzoylphenyl-(4-phenyl-phthalazin-1-yl)-amine
 3-cyanophenyl-(4-phenyl-phthalazin-1-yl)-amine
 5 3-ethoxycarbonylphenyl-(4-phenyl-phthalazin-1-yl)-amine
 3-pyridyl-(4-phenyl-phthalazin-1-yl)-amine

7. A process for the preparation of a compound according to claim 5 or 6, which comprises reacting an amino compound of formula (II)

10



- where $\text{R}^{3\text{A}}$ is R^3 as defined for formula (I) or a group convertible to R^3 and P is defined for
 15 formula (I).
 with a compound of formula (III)



20

(III)

- where Y is a group displaceable with an amine of formula (II) and $\text{R}^{1\text{A}}$ and $\text{R}^{2\text{A}}$ are R^1 and R^2 as defined for formula (I) or groups convertible to R^1 and R^2 ,
 25 and Q is as defined for formula (I),
 and where required converting a $\text{R}^{1\text{A}}$, $\text{R}^{2\text{A}}$ or $\text{R}^{3\text{A}}$ group to a R^1 , R^2 or R^3 group,
 converting one R^1 , R^2 or R^3 group to another R^1 , R^2 or R^3 group,
 converting a salt product to the free base or another pharmaceutically acceptable salt, or
 converting a free base product to a pharmaceutically acceptable salt.

INTERNATIONAL SEARCH REPORT

I. National Application No

PCT/EP 98/02172

CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D237/20 C07D237/34 A61K31/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 534 443 A (MITSUBISHI KASEI CORPORATION) 31 March 1993 see page 1 - page 6, line 26 ---	1,2
A	EP 0 514 277 A (ELF SANOFI) 19 November 1992 see the whole document ---	1,2
A	EP 0 382 634 A (ELF SANOFI) 16 August 1990 see the whole document ---	1,2
A	EP 0 073 161 A (SANOFI ELF) 2 March 1983 see the whole document ---	1,2
A	GB 2 063 249 A (MITSUBISHI YUKA PHARMACEUTICAL CO., LTD) 3 June 1981 cited in the application see the whole document -----	1,2

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 August 1998

Date of mailing of the international search report

01/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/02172

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1,4
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1,4
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/02172

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 534443	A	31-03-1993	JP 2730421 B	25-03-1998
			JP 6135938 A	17-05-1994
			CA 2078699 A	27-03-1993
			US 5462941 A	31-10-1995
			US 5324727 A	28-06-1994
EP 514277	A	19-11-1992	FR 2676444 A	20-11-1992
			AT 115569 T	15-12-1994
			AU 656770 B	16-02-1995
			AU 1627492 A	19-11-1992
			CA 2068770 A	17-11-1992
			CZ 282531 B	13-08-1997
			DE 69200895 D	26-01-1995
			DE 69200895 T	29-06-1995
			DK 514277 T	01-05-1995
			ES 2065755 T	16-02-1995
			FI 922235 A	17-11-1992
			GR 3015389 T	30-06-1995
			HU 9500577 A	30-10-1995
			IE 66926 B	07-02-1996
			IE 101885 A	04-08-1996
			JP 6073021 A	15-03-1994
			MX 9202282 A	01-12-1992
			NO 180233 B	02-12-1996
			NZ 242760 A	22-12-1994
			RU 2088577 C	27-08-1997
			US 5276036 A	04-01-1994
EP 382634	A	16-08-1990	FR 2642754 A	10-08-1990
			FR 2642757 A	10-08-1990
			CA 2009501 A	07-08-1990
			DE 69008566 D	09-06-1994
			DE 69008566 T	01-12-1994
			JP 2250871 A	08-10-1990
			PT 93060 A, B	31-08-1990
			US 5656631 A	12-08-1997
			US 5631255 A	20-05-1997
			US 5461053 A	24-10-1995
EP 73161	A	02-03-1983	FR 2511366 A	18-02-1983

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/02172

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 73161 A		AR 231537 A	28-12-1984
		AU 579570 B	01-12-1988
		AU 8702982 A	12-05-1983
		CA 1179347 A	11-12-1984
		CS 239929 B	16-01-1986
		DK 358782 A,B,	12-02-1983
		EG 15749 A	30-09-1986
		FI 822768 A,B,	11-02-1983
		JP 1768930 C	30-06-1993
		JP 4056032 B	07-09-1992
		JP 58038263 A	05-03-1983
		OA 7179 A	30-04-1984
		PT 75372 B	10-12-1984
		SU 1356960 A	30-11-1987
		US 4710499 A	01-12-1987
		ZA 8205515 A	29-06-1983
GB 2063249 A	03-06-1981	JP 1484065 C	27-02-1989
		JP 57048972 A	20-03-1982
		JP 63034871 B	12-07-1988
		JP 1435285 C	07-04-1988
		JP 56053660 A	13-05-1981
		JP 62042901 B	10-09-1987
		DE 3038166 A	21-05-1981
		FR 2468593 A	08-05-1981
		NL 8005411 A	13-04-1981